There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 7.7%, in the last year to ₹347.44 Cr. Its sector's average revenue growth for the last fiscal year was 19.46%.Annual Net Profit,rose 98.08% in the last year to ₹55.72 Cr. Its sector's average net profit growth for the last fiscal year was -20.75%.Price to Earning Ratio,is 21.41, lower than its sector PE ratio of 63.49.Q-Line Biotech was originally incorporated as ‘POCT Services Private Limited’ on November 10, 2010 as a Private limited company. Subsequently, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of the company was changed to ‘Q-Line Biotech Private Limited’. Further, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, the company was converted from a private limited company to public limited company and consequently the name of the company was changed to ‘Q-Line Biotech Limited’.The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and In Vitro Diagnostic (IVD) products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The core segments of operations of the company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices Rapids).Its key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices Rapids) and supplying/ manufacturing of in-vitro diagnostics, Pathology equipment’s devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own RD team developed a range of Covid testing kits viz.
RT-PCR Kits, RNA Extraction Kits, VTM Kits etc. It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its RD capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products.
The company works on a B2B model and supplying most of its products to its customers which includes distributors, diagnostic service providers and hospitals.Business area of the companyThe company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.Products and services of the companyReagentInstrumentConsumable/SpareServiceAwards, accreditations and recognition2022-23: Received the Certificate of Excellence from Boule for outstanding dedication and service to Boule products.2023-24: Received an Appreciation Award at JAI-CON 2023 during the 1st State Level Scientific Conference organized by JAI MLAP Punjab.2023-24: Received the Outstanding Distributor Award 2023 from Shenzhen Lifotronic Technology Co., Ltd. for their professionalism and valuable contribution.2023-24: In-house RD recognized by Government of India, Ministry of Science and Technology, Department of Scientific and Industrial Research (DSIR).2024-25: Awarded with Certificate of Appreciation for participation in Pharmatech Health East Africa and Medical Lab East Africa held in Dar Es Salaam, Tanzania.2024-25: Received the Golden Star Icon Award 2024 for pioneering work in In-Vitro Diagnostics Associated Equipment.2024-25: Awarded ‘Most Promising Company in IVD for Make in India initiative’ at the 15th MT India Healthcare Awards 2025 by Medgate Today Magazine.History and milestones2010-11: Incorporation of the company as a Private Limited Company in the name and style of ‘POCT Services Private Limited’ founded by Saurabh Garg, Amita Garg and Pushplata Garg.2014-15: First Branch office at Delhi 20-A Basement, Najafgarh Road, Shivaji Marg, West Delhi, New Delhi - 110015.2016-17: Established the first manufacturing facility at Plot No. 3, Pocket - H, Sector - 5, Bawana Industrial Complex, Bawana, Delhi – 110039, India.2018-19: Incorporated an associate company in the name of ‘POCT Science House Private Limited’.2020-21: Introduced Viral Transport Medium (VTM), Nucleic Acid Extraction Kit and Covid-19 RT-PCR Kit.2020-21: Expanded ELISA product range with HIV, HCV, and HBsAg kits.2021-22: Change of the name of the company from ‘POCT Services Private Limited’ to ‘Q-Line Biotech Private Limited’.2022-23: Expansion of office at Naraina Industrial Area, New Delhi.2023-24: Incorporated a subsidiary company in the name of ‘Q-Line Nutraceuticals Private Limited’.2023-24: Incorporated a subsidiary company in the name of ‘IQ-Line Private Limited’.2023-24: Incorporated an associate company in the name of ‘Q-Line Iris Private Limited’.2023-24: Established the manufacturing facility at Plot No.
276, Behtwa, Amausi, Station Road, Sarojni Nagar, Lucknow, Lucknow - 226009, Uttar Pradesh.2023-24: Established the manufacturing facility at Plot No. 3105, Gindan Khera, Amausi Station Road, Nadarganj, Lucknow226008, Uttar Pradesh.2023-24: Transferred its entire shareholding in ‘IQ-Line Private Limited’ which resulted in it no longer being a subsidiary company.2024-25: Established the manufacturing facility in 298 and 281, Adjacent Transport Nagar Metro station, Transport Nagar, Lucknow - 226023, Uttar Pradesh.2024-25: Conversion of the Private Limited Company into a Public Limited Company as per the provisions of the Companies Act, 2013.2024-25: Acquired shares in ‘Q-line Innovations Private Limited’, making it a subsidiary company.2024-25: Transferred its entire shareholding in ‘Q-Line Nutraceuticals Private Limited’ which resulted in it no longer being a subsidiary company.2024-25: Transferred its majority shareholding in ‘POCT Science House Private Limited’ which resulted in it no longer being an associate company.
Over the last 6 months, Q-Line Biotech Ltd has given a return of 7.75%. The stock was priced at ₹N/A on N/A and has risen to ₹510.25 as of 22 Jul 2026, a change of ₹N/A per share.
As of 22 Jul 2026, the share price of Q-Line Biotech Ltd is ₹510.25 on the NSE and ₹N/A on the BSE. The stock opened at ₹512.00, touched a high of ₹546.50 and a low of ₹490.30 during today's session.
Q-Line Biotech Ltd has delivered 7.75% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹600.00 on 23 Jun 2026 and a 52-week low of ₹431.00 on 29 May 2026. It is currently trading at ₹510.25 as of 22 Jul 2026.
The all-time high (ATH) for Q-Line Biotech Ltd was ₹586.80, recorded on 23 Jun 2026. At the current price of ₹510.25, the stock is trading 13.05% below its all-time high. The all-time low recorded was ₹453.35 on 01 Jun 2026.
Q-Line Biotech Ltd has delivered a return of 7.75% over the last 3 months. The stock was trading at ₹N/A on N/A and is currently at ₹510.25 as of 22 Jul 2026, reflecting a gain of ₹N/A per share over this period.
Q-Line Biotech Ltd has delivered a N/A% absolute return over the past 5 years, equivalent to a CAGR of N/A% per annum. The stock was priced at ₹N/A in Jul 2021 and has fallen to ₹510.25 as of 22 Jul 2026. An investment of ₹1,00,000 in Q-Line Biotech Ltd five years ago would be worth ₹N/A today.
No,Q-Line Biotech Ltd has not declared any dividend over the past 5 years. The company paid a total dividend of N/A per share between FY2022 and FY2026, with the most recent dividend of ₹N/A per share. At the current market price of ₹510.25, the trailing dividend yield of Q-Line Biotech Ltd stands at N/A%.
The intraday low for Q-Line Biotech Ltd on the NSE today was ₹490.30. The stock's 52-week low stands at ₹431.00, recorded on 29 May 2026. Today's low is 13.76% above the 52-week low, indicating the stock is trading well above its yearly lows.
For the most recent quarter, Q-Line Biotech Ltd reported: Revenue (Net Sales): ₹N/A Cr - N/A N/A% year-on-year from ₹N/A Cr in N/A. Net Income (PAT): ₹N/A Cr - N/A N/A% year-on-year from ₹N/A Cr in N/A.
The intraday high for Q-Line Biotech Ltd on the NSE today (22 Jul 2026) was ₹546.50. This compares to the 52-week high of ₹600.00 recorded on 23 Jun 2026. Today's high was -8.92% below the 52-week high.
